Valion Bio, Inc.SEC Filings
|
|
All SEC filings by Valion Bio, Inc. (VBIO) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.
Financials
| 10-Q | Quarterly report | View Diff | Aug 14, 2026 | |
| 10-Q | Quarterly report | View Diff | May 14, 2026 | |
| ARS | Annual report to shareholders | Apr 30, 2026 | ||
| 10-K | Annual report | View Diff | Mar 30, 2026 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2025 | |
| 10-Q | Quarterly report | View Diff | Aug 14, 2025 | |
| ARS | Annual report to shareholders | Jun 2, 2025 | ||
| 10-Q | Quarterly report | View Diff | May 15, 2025 | |
| 10-K | Annual report | View Diff | Mar 21, 2025 | |
| 10-Q | Quarterly report | View Diff | Nov 14, 2024 |
Events
| 8-K | Valion Bio Announces Changes to Management and Board of Directors | Sep 1, 2026 | ||
| 8-K | Valion Bio Announces Reverse Stock Split | Aug 27, 2026 | ||
| 8-K/A | Current report | Aug 20, 2026 | ||
| 8-K | Current report | Aug 17, 2026 | ||
| 8-K | Current report | Aug 6, 2026 | ||
| 8-K | Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion | Jul 14, 2026 | ||
| 8-K | Current report | Jun 18, 2026 | ||
| 8-K | Current report | Jun 3, 2026 | ||
| 8-K | Valion Bio Reports First Quarter 2026 Financial Results | May 14, 2026 | ||
| 8-K | Valion Bio Appoints Melinda Lackey as General Counsel | May 4, 2026 |
Registrations and Prospectuses
| RW | Registration withdrawal request | Aug 24, 2026 | ||
| S-1 | IPO registration | View Diff | Jul 17, 2026 | |
| S-8 | Registration of securities for employees | Jun 5, 2026 | ||
| S-8 | Registration of securities for employees | Jun 5, 2026 | ||
| 424B3 | Prospectus supplement | Apr 15, 2026 | ||
| S-1 | IPO registration | View Diff | Apr 13, 2026 | |
| DRS | Draft registration statement | Apr 6, 2026 | ||
| 424B3 | Prospectus supplement | Jan 20, 2026 | ||
| 424B3 | Prospectus supplement | Jan 20, 2026 | ||
| D | $75.00 Mm in Equity / Options / Securities to Be Acquired, Sold $12.00 Mm, 5 Investors | Dec 29, 2025 |
Proxies
| DEF 14A | Definitive proxy | View Diff | Jul 17, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Jul 7, 2026 | |
| DEF 14A | Definitive proxy | View Diff | Apr 30, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Apr 20, 2026 | |
| DEFA14A | Additional proxy soliciting materials | Feb 9, 2026 | ||
| DEF 14A | Definitive proxy | View Diff | Jan 9, 2026 | |
| PRE 14A | Preliminary proxy | View Diff | Dec 29, 2025 | |
| DEF 14A | Definitive proxy | View Diff | Jun 2, 2025 | |
| PRE 14A | Preliminary proxy | May 23, 2025 | ||
| DEF 14A | Definitive proxy | View Diff | Jan 3, 2025 |
Other
| EFFECT | Notice of effectiveness | Aug 13, 2026 | ||
| EFFECT | Notice of effectiveness | Apr 16, 2026 | ||
| CORRESP | Correspondence with SEC | Apr 13, 2026 | ||
| UPLOAD | Letter from SEC | Apr 9, 2026 | ||
| EFFECT | Notice of effectiveness | Jan 20, 2026 | ||
| EFFECT | Notice of effectiveness | Jan 20, 2026 | ||
| EFFECT | Notice of effectiveness | Sep 8, 2025 | ||
| CORRESP | Correspondence with SEC | Sep 3, 2025 | ||
| UPLOAD | Letter from SEC | Sep 3, 2025 | ||
| EFFECT | Notice of effectiveness | Aug 13, 2025 |
Ownership
| SC 13G/A | 3i, Lp Updates Stake in Valion Bio, Inc. | Sep 4, 2026 | ||
| SC 13D/A | 3i, Lp Updates Stake in Valion Bio, Inc. | Sep 3, 2026 | ||
| SC 13D/A | 3i, Lp Updates Stake in Valion Bio, Inc. | Sep 2, 2026 | ||
| SC 13D/A | 3i, Lp Updates Stake in Valion Bio, Inc. | Aug 27, 2026 | ||
| SC 13D/A | Beneficial ownership report | Aug 24, 2026 | ||
| SC 13D/A | Beneficial ownership report | Aug 19, 2026 | ||
| SC 13D/A | Beneficial ownership report | Aug 14, 2026 | ||
| SC 13D/A | Beneficial ownership report | Aug 11, 2026 | ||
| SC 13D | Beneficial ownership report | Aug 3, 2026 | ||
| SC 13G | Beneficial ownership report | Jul 17, 2026 |